MannKind Completes scPharmaceuticals Acquisition, Expects $370M Run Rate

MannKind Corporation has completed its acquisition of scPharmaceuticals, acquiring the FUROSCIX therapy for edema related to chronic heart failure and chronic kidney disease. This acquisition is expected to diversify and accelerate MannKind's double-digit revenue growth, with an annualized run rate projected to exceed $370 million by Q2 2025. MannKind aims to leverage the combined strengths of its endocrinology expertise and scPharmaceuticals' cardiovascular capabilities to expand FUROSCIX's reach among nephrologists and cardiologists. The acquisition also integrates scPharmaceuticals' experienced team into MannKind's commercial and medical infrastructure, enhancing its presence in cardiometabolic care. Additionally, MannKind filed the supplemental New Drug Application for the FUROSCIX ReadyFlow Autoinjector in Q3 2025 as planned. This strategic move supports MannKind's goal to build a patient-centric company delivering innovative therapies for chronic diseases, supported by a late-stage pipeline including treatments for lung disease and pulmonary fibrosis.